The Advanced Addiction Psychopharmacology Course is Going Virtual!
Saturday, November 7, 2020 and Saturday, November 14, 2020
The deadline to register for this course is October 31, 2020.
Who Should Attend?
This intensive, 12-hour, online course is designed for physicians and other health care professionals who have a foundation in prescribing medication for patients with substance use disorders, including those with co-occurring psychiatric conditions, but would like a deeper understanding of these pharmacotherapies. The Advanced Addiction Psychopharmacology Course will consist of two complementary components, including 9 on-demand video presentations, followed by a 2-day series of live webinar case discussions and Q&A sessions held on Saturday, November 7th from 12:00pm – 3:35pm ET and Saturday, November 14th from 12:00pm – 4:00pm ET. Course participants can earn up to 12 AMA PRA Category 1 Credits™.
This course is designed for learners with a foundational knowledge of addiction psychiatry will who wish to receive a more in-depth educational training in addiction psychopharmacology.
After participating in this course, learners should be able to:
- Describe how to use methadone, buprenorphine and naltrexone in clinical practice for the treatment of opioid use disorders.
- Describe medication treatments for alcohol use disorders.
- Determine when to use varenicline, bupropion, and nicotine replacement therapy (NRT) for treatment of nicotine use disorder.
- Discuss new evidence-based medication treatments for cocaine and methamphetamine use disorder.
- Discuss new evidence-based medication treatments for cannabis use disorder.
- Discuss medication approaches for the treatment of sedative-hypnotic use disorder.
- List evidence-based options for anti-depressant and anti-anxiety pharmacotherapy when treating patients with a co-occurring substance use disorder.
- Discuss evidence-based pharmacotherapy for treatment of ADHD with co-occurring substance use disorders.
- Discuss the pharmacotherapy of bipolar disorder in patients with co-occurring substance use disorder.